Uncategorized Archives - Page 3 of 151

MondayMar 02, 2026 9:00 am

Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy

There are several types of technologies for treating tumors with proton therapy, such as pencil beam scanning, passive scattering, and others Linac for Image Guided Hadron Therapy, LiGHT system, is believed to offer a more affordable, compact, and efficient design, along with better treatment precision than traditional technologies The system complements LIXTE’s lead clinical candidate, LB-100, which is a small-molecule PP2A inhibitor which is designed to enhance the activity of immunotherapy and chemotherapy Treating tumors with proton therapy is a highly advanced form of radiation that offers high precision, which minimizes radiation exposure for the tissue around the tumor. There…

WednesdayFeb 25, 2026 9:00 am

Earth Science Tech Inc. (ETST) Accelerates Profitability and Governance Transformation, Signals 40% Net Income Growth Trajectory

ETST reported a third fiscal quarter 2026 revenue of $8.4 million, up 14.1% year-over-year Gross margin expanded to 76.3%, highlighting an improved operating leverage across its portfolio The company announced governance reforms and cost initiatives expected to drive about $1.4 million in annualized savings and over 40% projected net income growth Earth Science Tech (OTC: ETST), a strategic holding company reputed for acquiring and growing high-potential operating businesses, is stepping into a new era of disciplined growth characterized by expanding margins, optimizing cash generation, and a total shift toward a more shareholder-focused public company model. In the company’s third fiscal…

MondayFeb 23, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands into Proton Therapy Through Liora Technologies, Advancing the LiGHT System for Next-Generation Cancer Care

LIXTE has acquired Liora Technologies Europe Ltd., securing its proprietary LiGHT system for advanced proton therapy treatment Liora works at the forefront of electronically controlled proton beam innovation, with its platform installed at the UK’s STFC Daresbury Laboratory These updates highlight LIXTE’s overarching mission to blend breakthrough drug development with transformative radiotherapy innovations in the global cancer fight Cancer is still one of the most widespread life-threatening diseases globally, with nearly all families affected either directly or as caregivers. Innovations in the medical ecosystem continue to gain momentum with the emergence of new immunotherapies, targeted drugs, and advanced radiation treatments.…

WednesdayFeb 18, 2026 9:45 am

When Cancer Care Hits a Hardware Wall, One Microcap Is Building Around It

In oncology, the biggest constraints are not always science. They are often the logistics, the cost of specialized infrastructure, and the difficulty of scaling advanced treatment capacity fast enough to meet demand. A Two-Track Strategy: Sensitizing Tumors, Modernizing Delivery LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) is pursuing a model that tries to improve cancer outcomes from two directions at once. On the therapeutic side, the company’s lead asset is LB-100, a clinical-stage compound designed to inhibit protein phosphatase 2A (“PP2A”), a biological target involved in cellular stress response and DNA repair pathways. LIXTE’s stated strategy is not to replace standard…

FridayFeb 13, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Focused on Dual Narratives of Scientific Progress, Social Engagement

LIXTE recently announced advances in its approach to cancer therapy through its proprietary compound LB-100 Alongside clinical development news, LIXTE is sponsoring the Good Health: Mind, Body & Soul Summit These two announcements paint a picture of a company advancing on multiple fronts LIXTE Biotechnology Holdings (NASDAQ: LIXT) is entering 2026 with momentum on both scientific and community fronts, announcing progress in its lead oncology program while also sponsoring a major health and wellness summit focused on addressing disparities in care. The company’s announcements highlight advances surrounding LB-100, its first-in-class cancer therapy candidate designed to enhance the effectiveness of existing treatments and underscore…

FridayFeb 13, 2026 9:00 am

Earth Science Tech Inc. (ETST) Driving Growth Through Strategic Healthcare Integration

ETST operates as an active strategic holding company, acquiring and optimizing businesses through direct management and governance. The company’s core operations focus on the health and wellness sector via a vertically integrated portfolio. ETST’s mission centers on building durable shareholder value through regulatory discipline, operational control, and scalable growth platforms. A Hands-On Approach to Portfolio Management Earth Science Tech (OTC: ETST) is redefining the traditional holding company model by building a diversified portfolio designed for long-term sustainability. Unlike passive investment vehicles, ETST takes an active role in its subsidiaries, utilizing hands-on management and disciplined execution to enhance performance across the board.…

ThursdayFeb 12, 2026 10:30 am

HeartBeam Inc. (NASDAQ: BEAT) Highlighted Among Medical Device Innovators as FDA Clearances Set Tone for New Year

HeartBeam was included in a report published by Modern Healthcare that highlighted companies that achieved meaningful regulatory milestones or demonstrated forward momentum. HeartBeam’s technology is aligned with evolving regulatory and clinical priorities. In addition to being listed in the Modern Healthcare report, the company was also included in PatentVest’s “Total Cardiac Intelligence” report. HeartBeam (NASDAQ: BEAT) was recently recognized among a select group of medical device companies featured in a January industry roundup highlighting recent U.S. Food and Drug Administration (“FDA”) clearances and approvals across the sector. The recognition underscores HeartBeam’s progress as it advances a novel approach to cardiac diagnostics through…

TuesdayFeb 10, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology

One of the key advantages of photodynamic therapy is its selectivity. Soligenix is advancing HyBryte(TM), or SGX301, designed for the treatment of cutaneous T-cell lymphoma. The company has achieved an important safety milestone in its confirmatory phase 3 clinical trial of HyBryte for CTCL treatment. From lab research to clinical application, photodynamic therapy (“PDT”) is emerging as a powerful treatment approach that uses light and chemistry to selectively target diseased tissue. As this modality gains attention for its precision and safety profile, Soligenix (NASDAQ: SNGX) is developing light-activated therapies designed to treat cutaneous T-cell lymphoma (“CTCL”) and other inflammatory skin diseases using targeted photodynamic…

MondayFeb 09, 2026 9:45 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment

LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system This system provides several advantages over technologies that are currently available for treating tumors with proton therapy The LiGHT system also complements LIXTE’s LB-100, which is the company’s lead clinical candidate that’s designed to help boost the activity of both chemotherapy and immunotherapy LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, recently acquired Liora Technologies, a company that’s pioneering proton therapy systems for treating tumors in various types of cancers. Liora is becoming a wholly owned subsidiary of LIXTE, and the acquisition also includes Liora’s proprietary flagship…

ThursdayFeb 05, 2026 9:00 am

The Anti-Dilution Playbook: How Earth Science Tech Inc. (ETST) Rewrote the OTC Capital Structure Narrative

The company has issued zero common shares since October 2023, marking a decisive break from typical OTC dilution patterns. A multi-year share repurchase program has retired more than 20 million shares while authorized shares have been reduced by 60%. Earth Science Tech is funding operations and acquisitions through cash flow while legally restricting its future ability to dilute shareholders. In the microcap market, capital formation is often synonymous with dilution. Companies raise money by issuing new shares, frequently at the expense of long-term shareholders, creating a cycle where growth in operations does not translate into growth in per-share value. Against…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Liora, a subsidiary of LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), Introduces New CEO, Brings Experience to Treating Tumors with Proton Therapy

Earth Science Tech Inc. (ETST) Accelerates Profitability and Governance Transformation, Signals 40% Net Income Growth Trajectory

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Expands into Proton Therapy Through Liora Technologies, Advancing the LiGHT System for Next-Generation Cancer Care

When Cancer Care Hits a Hardware Wall, One Microcap Is Building Around It

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Focused on Dual Narratives of Scientific Progress, Social Engagement

Earth Science Tech Inc. (ETST) Driving Growth Through Strategic Healthcare Integration

HeartBeam Inc. (NASDAQ: BEAT) Highlighted Among Medical Device Innovators as FDA Clearances Set Tone for New Year

Soligenix Inc. (NASDAQ: SNGX) Driving Innovation in Photodynamic Therapy Potential in Oncology, Dermatology

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment

The Anti-Dilution Playbook: How Earth Science Tech Inc. (ETST) Rewrote the OTC Capital Structure Narrative

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search